E-LIB Suche - Ergebnisse für: Tausch, E.

1

Deep learning can predict presence of TP53 aberrations and ..:

Pachong, S. Mebwe ; Robrecht, S. ; Ligtvoet, R....
Hematological Oncology. 41 (2023) S2 - p. 305-306 , 2023

Link: https://doi.org/10.1002/..

2

Safety of acalabrutinib treatment in very old (≥80 y) and/o..:

Simon, F. ; Ligtvoet, R. ; Nösslinger, T....
Hematological Oncology. 41 (2023) S2 - p. 468-469 , 2023

Link: https://doi.org/10.1002/..

3

Characterization of the genetic and epigenetic landscape of..:

Drewes, C. ; López, C. ; Okeke, N....
Hematological Oncology. 41 (2023) S2 - p. 248-248 , 2023

Link: https://doi.org/10.1002/..

4

VENETOCLAX‐OBINUTUZUMAB FOR PREVIOUSLY UNTREATED CHRONIC LY..:

Al‐Sawaf, O. ; Robrecht, S. ; Zhang, C....
Hematological Oncology. 41 (2023) S2 - p. 58-60 , 2023

Link: https://doi.org/10.1002/..

5

IBRUTINIB VERSUS PLACEBO IN PATIENTS WITH ASYMPTOMATIC, TRE..:

Langerbeins, P. ; Robrecht, S. ; Nieper, P....
Hematological Oncology. 41 (2023) S2 - p. 56-58 , 2023

Link: https://doi.org/10.1002/..

6

A PHASE 3 TRIAL OF ACALABRUTINIB, OBINUTUZUMAB AND VENETOCL..:

Kutsch, N. ; Fink, A. M. ; Robrecht, S....
Hematological Oncology. 41 (2023) S2 - p. 851-853 , 2023

Link: https://doi.org/10.1002/..

7

S146: VENETOCLAX IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKE..:

Stilgenbauer, S. ; Tausch, E. ; Roberts, A. W....
HemaSphere. 6 (2022) - p. 47-48 , 2022

Link: https://doi.org/10.1097/..

8

S148: VENETOCLAX-OBINUTUZUMAB FOR PREVIOUSLY UNTREATED CHRO..:

Al-Sawaf, O. ; Zhang, C. ; Robrecht, S....
HemaSphere. 6 (2022) - p. 49-50 , 2022

Link: https://doi.org/10.1097/..

9

P641: RETREATMENT WITH VENETOCLAX AFTER VENETOCLAX, OBINUTU..:

Cramer, P. ; Fürstenau, M. ; Giza, A....
HemaSphere. 6 (2022) - p. 539-540 , 2022

Link: https://doi.org/10.1097/..

10

S143: TRANSCRIPTOMIC CHARACTERIZATION OF MRD RESPONSE AND N..:

Al-Sawaf, O. ; Jin, H. Y. ; Zhang, C....
HemaSphere. 6 (2022) - p. 44-45 , 2022

Link: https://doi.org/10.1097/..

11

BENDAMUSTINE, FOLLOWED BY OBINUTUZUMAB, ACALABRUTINIB AND V..:

Cramer, P ; Fürstenau, M ; Robrecht, S...
Hematological Oncology. 39 (2021) S2 - p. , 2021

Link: https://doi.org/10.1002/..

12

GENETIC MARKERS AND OUTCOME WITH FRONT LINE OBINUTUZUMAB PL..:

Tausch, E ; Schneider, C ; Yosifov, D...
Hematological Oncology. 39 (2021) S2 - p. , 2021

Link: https://doi.org/10.1002/..

13

VENETOCLAX‐OBINUTUZUMAB MODULATES CLONAL GROWTH: RESULTS OF..:

Al‐Sawaf, O ; Zhang, C ; Lu, T...
Hematological Oncology. 39 (2021) S2 - p. , 2021

Link: https://doi.org/10.1002/..

14

VENETOCLAX‐OBINUTUZUMAB FOR PREVIOUSLY UNTREATED CHRONIC LY..:

Al‐Sawaf, O. ; Zhang, C. ; Robrecht, S....
Hematological Oncology. 39 (2021) S2 - p. , 2021

Link: https://doi.org/10.1002/..

15

THE CLL‐RT1 TRIAL: A MULTICENTER PHASE‐2 TRIAL OF ZANUBRUTI..:

Al‐Sawaf, O. ; Robrecht, S. ; Stumpf, J....
Hematological Oncology. 39 (2021) S2 - p. , 2021

Link: https://doi.org/10.1002/..